Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

311.72
-4.3600-1.38%
Post-market: 312.290.5680+0.18%19:57 EDT
Volume:193.65K
Turnover:60.70M
Market Cap:18.76B
PE:33.84
High:316.68
Open:315.93
Low:311.37
Close:316.08
52wk High:330.75
52wk Low:260.42
Shares:60.18M
Float Shares:60.18M
Volume Ratio:1.10
T/O Rate:0.32%
Dividend:4.61
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.51

Loading ...

OverviewCompanyNewsFilings

Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On

Reuters
·
Sep 22

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Nvidia Corp., Merck Share Gains Lead Dow's 425-Point Climb

Dow Jones
·
Sep 22

Exchange-Traded Funds Rise as US Equities Advance After Midday

MT Newswires Live
·
Sep 22

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

J&J says Caplyta Phase 3 study in bipolar I met primary endpoint

TIPRANKS
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

AbbVie, Iambic Sign Multiyear Drug Discovery Deal

MT Newswires Live
·
Sep 21

AbbVie Partners with Iambic to Accelerate AI-Driven Small-Molecule Drug Discovery

Reuters
·
Sep 21

Johnson & Johnson Says Phase 3 Trial Shows Caplyta Cuts Bipolar I Mania Symptoms by Week 3

Reuters
·
Sep 21

Abbvie and Iambic Announce Collaboration to Accelerate AI-Driven Drug Discovery

THOMSON REUTERS
·
Sep 21

Abbvie - Iambic to Receive Upfront Payment, Milestone Payments, and Tiered Royalties from Collaboration

THOMSON REUTERS
·
Sep 21

Abbvie - Partnership to Accelerate Small Molecule Drug Discovery in Immunology, Neuroscience, Oncology

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Demonstrates Statistically Significant Rapid Reduction in Manic Symptoms at Week 3

THOMSON REUTERS
·
Sep 21

Caplyta® (Lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Pivotal Phase 3 Study

THOMSON REUTERS
·
Sep 21

J&J - Caplyta Well-Tolerated; Dry Mouth and Nausea Most Common Adverse Events

THOMSON REUTERS
·
Sep 21

Adarx Pharmaceuticals: IPO Price Expected Between $15 and $17 Per Share

Reuters
·
Sep 21
More